✦ LIBER ✦

Solanezumab was safe and well-tolerated for Asian patients with mild-to-moderate Alzheimer's disease in a multicenter, randomized, open-label, multi-dose study

✍ Scribed by Taro Goto; Shinji Fujikoshi; Kazunori Uenaka; Shinichi Nishiuma; Eric R. Siemers; Robert A. Dean; Michihiro Takahashi

Book ID: 118465869
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 45 KB
Volume: 6
Category: Article
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2010.05.1003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Open label, multicenter, 28-week extensi

Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease

✍ Brian R. Ott; Lesley M. Blake; Ethel Kagan; Malca Resnick; for the Memantine MEM 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 142 KB

P.5.a.006 Long-term safety and tolerabil

P.5.a.006 Long-term safety and tolerability of memantine: an open-label extension study in patients with mild to moderate Alzheimer's disease

✍ S. Bakchine; M. Rainer 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Effect of combination therapy with meman

Effect of combination therapy with memantine and rivastigmine transdermal patch on BPSD in patients with mild-to-moderate Alzheimer's disease: A 24-week prospective, multicenter, randomized, open-label clinical trial

✍ Na, Hae Ri; Choi, Seong; Yoon, Soo Jin; Park, Kyung Won; Kim, Byeong Chae; Lee, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Effect of combination therapy with meman

Effect of combination therapy with memantine and rivastigmine patch on agitation behavior in patients with mild-to-moderate Alzheimer's disease: A 24-week prospective, multicenter, randomized, open-label clinical trial

✍ Yoon, Soo Jin 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 55 KB

A multicentre, randomized, double-blind,

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study

✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre

P.4.041 Donepezil is a well-tolerated lo

P.4.041 Donepezil is a well-tolerated long-term treatment for patients with mild to moderate Alzheimer's disease: Results from a patient cohort who completed a one-year placebo-controlled study and participated in a two-year follow-up study

✍ B. Winblad; K. Engedal; H. Soininen; F.R.J. Verhey; G. Waldemar; A. Wimo; A.-L. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 286 KB